Falk, R. H., Kruger, J. & Quarta, C. C. Senile systemic amyloidosis is a markedly underdiagnosed cardiomyopathy: experience of a cardiac amyloidosis program [abstract]. J. Am. Coll. Cardiol. 61 (Suppl. 10), E1241 (2013).
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M. & Rapezzi, C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135, 1357–1377 (2017).
Wechalekar, A. D., Gillmore, J. D. & Hawkins, P. N. Systemic amyloidosis. Lancet 387, 2641–2654 (2016).
Pinney, J. H. et al. Systemic amyloidosis in England: an epidemiological study. Br. J. Haematol. 161, 525–532 (2013).
Gertz, M. A., Lacy, M. Q., Dispenzieri, A. & Hayman, S. R. Amyloidosis. Best Pract. Res. Clin. Haematol. 18, 709–727 (2005).
Merlini, G. CyBorD: stellar response rates in AL amyloidosis. Blood 119, 4343–4345 (2012).
Falk, R. H., Alexander, K. M., Liao, R. & Dorbala, S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J. Am. Coll. Cardiol. 68, 1323–1341 (2016).
Muchtar, E. et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129, 2111–2119 (2017).
Jaccard, A. et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 99, 1479–1485 (2014).
Mirzoyev, S. A. et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction [abstract]. Circulation 122 (Suppl. 21), 17926 (2010).
Cornwell, G. G., Murdoch, W. L., Kyle, R. A., Westermark, P. & Pitkanen, P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am. J. Med. 75, 618–623 (1983).
Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann. Med. 40, 232–239 (2008).
Rapezzi, C. et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat. Rev. Cardiol. 7, 398–408 (2010).
Connors, L. H., Lim, A., Prokaeva, T., Roskens, V. A. & Costello, C. E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10, 160–184 (2003).
Merlini, G. & Westermark, P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J. Intern. Med. 255, 159–178 (2004).
Pinney, J. H. et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J. Am. Heart Assoc. 2, e000098 (2013).
Connors, L. H. et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am. Heart J. 158, 607–614 (2009).
Buxbaum, J. N. & Ruberg, F. L. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet. Med. 19, 733–742 (2017).
Rapezzi, C. et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120, 1203–1212 (2009).
Gillmore, J. D. et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39, 2799–2806 (2018).
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).
Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22–31 (2018).
Berk, J. L. et al. Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. JAMA 310, 2658–2667 (2013).
Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007–1016 (2018).
Lane, T. et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140, 16–26 (2019).
Martinez-Naharro, A., Hawkins, P. N. & Fontana, M. Cardiac amyloidosis. Clin. Med. 18, s30–s35 (2018).
Longhi, S. et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid 22, 147–155 (2015).
Mints, Y. Y., Doros, G., Berk, J. L., Connors, L. H. & Ruberg, F. L. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 5, 772–779 (2018).
Martinez-Naharro, A. et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J. Am. Coll. Cardiol. 73, 1733–1734 (2019).
Feng, D. et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119, 2490–2497 (2009).
Grogan, M. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J. Am. Coll. Cardiol. 68, 1014–1020 (2016).
Comenzo, R. L. et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26, 2317–2325 (2012).
Sperry, B. W. et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int. J. Cardiol. 214, 477–481 (2016).
Dubrey, S. W. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91, 141–157 (1998).
Murtagh, B. et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am. J. Cardiol. 95, 535–537 (2005).
Habib, G. et al. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document in collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by the Indian Academy of Echocardiography. Eur. Heart J. Cardiovasc. Imaging 18, 1090–1121 (2017).
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872–2891 (2019).
Cyrille, N. B., Goldsmith, J., Alvarez, J. & Maurer, M. S. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am. J. Cardiol. 114, 1089–1093 (2014).
Dungu, J. et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am. Heart J. 164, 72–79 (2012).
Fontana, M. et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277, 388–397 (2015).
Martinez-Naharro, A. et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc. Imaging 12, 810–819 (2019).
Hongo, M. et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am. J. Cardiol. 85, 849–853 (2000).
Pozo, E. et al. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart 100, 1688–1695 (2014).
Falk, R. H. Diagnosis and management of the cardiac amyloidoses. Circulation 112, 2047–2060 (2005).
Gertz, M. A. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am. J. Hematol. 79, 319–328 (2005).
Austin, B. A. et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am. J. Cardiol. 103, 1429–1433 (2009).
Knight, D. S. et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc. Imaging 12, 823–833 (2019).
Tsang, W. & Lang, R. M. Echocardiographic evaluation of cardiac amyloid. Curr. Cardiol. Rep. 12, 272–276 (2010).
Klein, A. L. et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J. Am. Coll. Cardiol. 13, 1017–1026 (1989).
Pagourelias, E. D. et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ. Cardiovasc. Imaging 10, e005588 (2017).
Pewsner, D. et al. Ruling a diagnosis in or out with “SpPIn” and “SnNOut”: a note of caution. BMJ 329, 209–213 (2004).
Phelan, D. et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98, 1442–1448 (2012).
Senapati, A. et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 102, 748–754 (2016).
Rapezzi, C. & Fontana, M. Relative left ventricular apical sparing of longitudinal strain in cardiac amyloidosis is it just amyloid infiltration? JACC Cardiovasc. Imaging 12, 1174–1176 (2019).
Rapezzi, C. & Fontana, M. Relative left ventricular apical sparing of longitudinal strain in cardiac amyloidosis: is it just amyloid infiltration? JACC Cardiovasc. Imaging 12, 1174–1176 (2019).
Pennell, D. J. Cardiovascular magnetic resonance: twenty-first century solutions in cardiology. Clin. Med. 3, 273–278 (2003).
Martinez-Naharro, A. et al. Magnetic resonance in transthyretin cardiac amyloidosis. J. Am. Coll. Cardiol. 70, 466–477 (2017).
White, S. K. et al. T1 mapping for myocardial extracellular volume measurement by CMR bolus only versus primed infusion technique. JACC Cardiovasc. Imaging 6, 955–962 (2013).
Reiter, T. et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 14, 31 (2012).
Koenig, S. H., Spiller, M., Brown, R. D. III & Wolf, G. L. Relaxation of water protons in the intra- and extracellular regions of blood containing Gd(DTPA). Magn. Reson. Med. 3, 791–795 (1986).
Kim, R. J. et al. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 100, 185–192 (1999).
Rehwald, W. G., Fieno, D. S., Chen, E. L., Kim, R. J. & Judd, R. M. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 105, 224–229 (2002).
Maceira, A. M. et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111, 186–193 (2005).
Fontana, M., Chung, R., Hawkins, P. N. & Moon, J. C. Cardiovascular magnetic resonance for amyloidosis. Heart Fail. Rev. 20, 133–144 (2015).
Kwong, R. Y. & Falk, R. H. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111, 122–124 (2005).
Fontana, M. et al. A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Med. Imaging 17, 3 (2017).
Moon, J. C. et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J. Cardiovasc. Magn. Reson. 15, 92 (2013).
Kellman, P., Arai, A. E., McVeigh, E. R. & Aletras, A. H. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn. Reson. Med. 47, 372–383 (2002).
Fontana, M. et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132, 1570–1579 (2015).
Bollee, G. et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin. J. Am. Soc. Nephrol. 3, 375–381 (2008).
Lachmann, H. J. & Gillmore, J. D. Renal amyloidosis. Br. J. Hosp. Med. 71, 83–86 (2010).
Fontana, M. et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc. Imaging 7, 157–165 (2014).
Karamitsos, T. D. et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc. Imaging 6, 488–497 (2013).
Sado, D. M. et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 6, 392–398 (2013).
Baggiano, A. et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13, 69–80 (2020).
Banypersad, S. M. et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur. Heart J. 36, 244–251 (2015).
Banypersad, S. M. et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ. Cardiovasc. Imaging 6, 34–39 (2013).
Martinez-Naharro, A. et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc. Imaging 11, 152–154 (2018).
Kotecha, T. et al. Myocardial edema and prognosis in amyloidosis. J. Am. Coll. Cardiol. 71, 2919–2931 (2018).
Kellman, P. et al. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. J. Cardiovasc. Magn. Reson. 19, 43 (2017).
Shirahama, T. & Cohen, A. S. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol. 33, 679–708 (1967).
Nordlinger, M., Magnani, B., Skinner, M. & Falk, R. H. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am. J. Cardiol. 96, 982–984 (2005).
Martinez-Naharro, A. et al. Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping [abstract 028]. Heart 103 (Suppl. 1), A24 (2017).
Wizenberg, T. A., Muz, J., Sohn, Y. H., Samlowski, W. & Weissler, A. M. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am. Heart J. 103, 468–473 (1982).
Puille, M. et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur. J. Nucl. Med. Mol. Imaging 29, 376–379 (2002).
Bokhari, S., Shahzad, R., Castano, A. & Maurer, M. S. Nuclear imaging modalities for cardiac amyloidosis. J. Nucl. Cardiol. 21, 175–184 (2014).
Bokhari, S. et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ. Cardiovasc. Imaging 6, 195–201 (2013).
Castano, A. et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 1, 880–889 (2016).
Perugini, E. et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J. Am. Coll. Cardiol. 46, 1076–1084 (2005).
Rapezzi, C. et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc. Imaging 4, 659–670 (2011).
Papantoniou, V. et al. Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy. Hell. J. Nucl. Med. 18, 42–50 (2015).
Galat, A. et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 22, 210–220 (2015).
Glaudemans, A. W. et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 21, 35–44 (2014).
Rapezzi, C., Gagliardi, C. & Milandri, A. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. J. Nucl. Cardiol. 26, 1638–1641 (2019).
Pilebro, B. et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups. J. Med. Sci. 121, 17–24 (2016).
Stats, M. A. & Stone, J. R. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc. Pathol. 25, 413–417 (2016).
Falk, R. H., Lee, V. W., Rubinow, A., Hood, W. B. Jr. & Cohen, A. S. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am. J. Cardiol. 51, 826–830 (1983).
Hutt, D. F. et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur. Heart J. Cardiovasc. Imaging 15, 1289–1298 (2014).
Gillmore, J. D. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133, 2404–2412 (2016).
Vandenberghe, R. et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68, 319–329 (2010).
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804 (2012).
Dorbala, S. et al. Imaging cardiac amyloidosis: a pilot study using (18)F-florbetapir positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 41, 1652–1662 (2014).
Osborne, D. R., Acuff, S. N., Stuckey, A. & Wall, J. S. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir. Front. Cardiovasc. Med. 2, 23 (2015).
Antoni, G. et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J. Nucl. Med. 54, 213–220 (2013).
Lee, S. P. et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc. Imaging 8, 50–59 (2015).
Law, W. P., Wang, W. Y., Moore, P. T., Mollee, P. N. & Ng, A. C. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J. Nucl. Med. 57, 1733–1739 (2016).
Paulus, W. J. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 28, 2539–2550 (2007).
Komajda, M. & Lam, C. S. Heart failure with preserved ejection fraction: a clinical dilemma. Eur. Heart J. 35, 1022–1032 (2014).
Gonzalez-Lopez, E. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 36, 2585–2594 (2015).
Treibel, T. A. et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ. Cardiovasc. Imaging 9, e005066 (2016).
Longhi, S. et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc. Imaging 7, 531–532 (2014).
Cavalcante, J. L. et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J. Cardiovasc. Magn. Reson. 19, 98 (2017).
Castano, A. et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J. 38, 2879–2887 (2017).
Moon, J. C. et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. 24, 2151–2155 (2003).
Shah, K. B. et al. Transthyretin cardiac amyloidosis in black Americans. Circ. Heart Fail. 9, e002558 (2016).
Vogelsberg, H. et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J. Am. Coll. Cardiol. 51, 1022–1030 (2008).
Austin, B. A. et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc. Imaging 2, 1369–1377 (2009).
Ruberg, F. L. et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am. J. Cardiol. 103, 544–549 (2009).
Syed, I. S. et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc. Imaging 3, 155–164 (2010).
Damy, T. et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur. Heart J. 37, 1826–1834 (2016).
Sperry, B. W. et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J. Am. Coll. Cardiol. 72, 2040–2050 (2018).
Fosbol, E. L. et al. Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes. J. Am. Coll. Cardiol. 74, 15–23 (2019).
Dispenzieri, A. et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103, 3960–3963 (2004).
Mohty, D. et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch. Cardiovasc. Dis. 104, 611–618 (2011).
Klein, A. L. et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 83, 808–816 (1991).
Koyama, J. & Falk, R. H. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc. Imaging 3, 333–342 (2010).
Siepen, F. A. D. et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin. Res. Cardiol. 107, 158–169 (2018).
Kotecha, T., Martinez-Naharro, A., Gillmore, J. D., Hawkins, P. N. & Fontana, M. Reply: Amyloidosis in the era of mass spectrometry-based proteomics. J. Am. Coll. Cardiol. 72, 1881 (2018).
Hutt, D. F. et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur. Heart J. Cardiovasc. Imaging 18, 1344–1350 (2017).
Dispenzieri, A. et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 22, 3751–3757 (2004).
Emdin, M. et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin. Chem. Lab. Med. 42, 627–636 (2004).
Clerico, A. & Emdin, M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin. Chem. 50, 33–50 (2004).
Rysava, R. AL amyloidosis: advances in diagnostics and treatment. Nephrol. Dial. Transplant 34, 1460–1466 (2019).
Richards, D. B. et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N. Engl. J. Med. 373, 1106–1114 (2015).
